nach oben

Current Diabetes Reports

Erschienen in:

01.03.2017 | Microvascular Complications—Nephropathy (M Afkarian, Section Editor)

Caveolin-1 in the Pathogenesis of Diabetic Nephropathy: Potential Therapeutic Target?

verfasst von: Richard Van Krieken, Joan C. Krepinsky

Erschienen in: Current Diabetes Reports | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose of review

Diabetic nephropathy, a major microvascular complication of diabetes and the most common cause of end-stage renal disease, is characterized by prominent accumulation of extracellular matrix. The membrane microdomains caveolae, and their integral protein caveolin-1, play critical roles in the regulation of signal transduction. In this review we discuss current knowledge of the contribution of caveolin-1/caveolae to profibrotic signaling and the pathogenesis of diabetic kidney disease, and assess its potential as a therapeutic target.

Recent findings

Caveolin (cav)-1 is key to facilitating profibrotic signal transduction induced by several stimuli known to be pathogenic in diabetic nephropathy, including the most prominent factors hyperglycemia and angiotensin II. Phosphorylation of cav-1 on Y14 is an important regulator of these responses. In vivo studies support a pathogenic role for caveolae in the progression of diabetic nephropathy.

Summary

Targeting caveolin-1/caveolae would enable inhibition of multiple profibrotic pathways, representing a novel and potentially potent therapeutic option for diabetic nephropathy.

Dronavalli S, Duka I, Bakris GL. The pathogenesis of diabetic nephropathy. Nat Clin Pract Endocrinol Metab. 2008;4(8):444–52. doi:10.1038/ncpendmet0894.CrossRefPubMed

Gosmanov AR, Wall BM, Gosmanova EO. Diagnosis and treatment of diabetic kidney disease. Am J Med Sci. 2014;347(5):406–13. doi:10.1097/MAJ.0000000000000185.CrossRefPubMed

Ziyadeh FN. Mediators of diabetic renal disease: the case for tgf-Beta as the major mediator. J Am Soc Nephrol. 2004;15 Suppl 1:S55–7.CrossRefPubMed

Cohen AW, Hnasko R, Schubert W, Lisanti MP. Role of caveolae and caveolins in health and disease. Physiol Rev. 2004;84(4):1341–79. doi:10.1152/physrev.00046.2003.CrossRefPubMed

Parton RG, Simons K. The multiple faces of caveolae. Nat Rev Mol Cell Biol. 2007;8(3):185–94. doi:10.1038/nrm2122.CrossRefPubMed

•• Moriyama T, Tsuruta Y, Shimizu A, Itabashi M, Takei T, Horita S, et al. The significance of caveolae in the glomeruli in glomerular disease. J Clin Pathol. 2011;64(6):504–9. doi:10.1136/jcp.2010.087023. This is the only study assessing cav-1 expression in various glomerular renal diseases, including diabetic nephropathy, in humans. Increased glomerular cav-1 expression, as well as an increase in the number of caveolae in glomerular endothelial cells, was shown. Importantly, cav-1 expression correlated with the degree of albuminuria.

Razani B, Wang XB, Engelman JA, Battista M, Lagaud G, Zhang XL, et al. Caveolin-2-deficient mice show evidence of severe pulmonary dysfunction without disruption of caveolae. Mol Cell Biol. 2002;22(7):2329–44.CrossRefPubMedPubMedCentral

•• Li XC, Gu V, Miguel-Qin E, Zhuo JL. Role of caveolin 1 in AT1a receptor-mediated uptake of angiotensin II in the proximal tubule of the kidney. Am J Physiol Ren Physiol. 2014;307(8):F949–61. doi:10.1152/ajprenal.00199.2014. This study showed a major role for cav-1 in mediating angiotensin II uptake, and thus responses, in proximal tubules. This correlated functionally with lower responsiveness to angiotensin II infusion in cav-1 knockout mice.

Tamai O, Oka N, Kikuchi T, Koda Y, Soejima M, Wada Y, et al. Caveolae in mesangial cells and caveolin expression in mesangial proliferative glomerulonephritis. Kidney Int. 2001;59(2):471–80. doi:10.1046/j.1523-1755.2001.059002471.x.CrossRefPubMed

10.

Grande G, Rippe C, Rippe A, Rahman A, Sward K, Rippe B. Unaltered size selectivity of the glomerular filtration barrier in caveolin-1 knockout mice. Am J Physiol Ren Physiol. 2009;297(2):F257–62. doi:10.1152/ajprenal.00075.2009.CrossRef

11.

Sorensson J, Fierlbeck W, Heider T, Schwarz K, Park DS, Mundel P, et al. Glomerular endothelial fenestrae in vivo are not formed from caveolae. J Am Soc Nephrol. 2002;13(11):2639–47.CrossRefPubMed

12.

Sindhu RK, Ehdaie A, Vaziri ND, Roberts CK. Effects of chronic renal failure on caveolin-1, guanylate cyclase and AKT protein expression. Biochim Biophys Acta. 2004;1690(3):231–7. doi:10.1016/j.bbadis.2004.06.013.CrossRefPubMed

13.

Schlondorff D, Banas B. The mesangial cell revisited: no cell is an island. J Am Soc Nephrol. 2009;20(6):1179–87. doi:10.1681/asn.2008050549.CrossRefPubMed

14.

Peng F, Wu D, Ingram AJ, Zhang B, Gao B, Krepinsky JC. RhoA activation in mesangial cells by mechanical strain depends on caveolae and caveolin-1 interaction. J Am Soc Nephrol. 2007;18(1):189–98. doi:10.1681/ASN.2006050498. ASN.2006050498 [pii].

15.

Peng F, Zhang B, Wu D, Ingram AJ, Gao B, Krepinsky JC. TGFbeta-induced RhoA activation and fibronectin production in mesangial cells require caveolae. Am J Physiol Ren Physiol. 2008;295(1):F153–64. doi:10.1152/ajprenal.00419.2007.CrossRef

16.

Zhang B, Peng F, Wu D, Ingram AJ, Gao B, Krepinsky JC. Caveolin-1 phosphorylation is required for stretch-induced EGFR and Akt activation in mesangial cells. Cell Signal. 2007;19(8):1690–700. doi:10.1016/j.cellsig.2007.03.005.CrossRefPubMed

17.

Zhang N, Ji Z. Effects of caveolin-1 and P-ERK1/2 on Ang II-induced glomerular mesangial cell proliferation. Ren Fail. 2013;35(7):971–7. doi:10.3109/0886022X.2013.808956.CrossRefPubMed

18.

• Zhang Y, Peng F, Gao B, Ingram AJ, Krepinsky JC. High glucose-induced RhoA activation requires caveolae and PKCbeta1-mediated ROS generation. Am J Physiol Ren Physiol. 2012;302(1):F159–72. doi:10.1152/ajprenal.00749.2010. This is the first paper to highlight the importance of caveolae to glucose-induced generation of ROS. It further showed the necessity of caveolae to activation of PKCβ, upstream of ROS, and ultimately to upregulation of profibrotic TGFβ1.

19.

Lan HY, Chung AC. TGF-beta/Smad signaling in kidney disease. Semin Nephrol. 2012;32(3):236–43. doi:10.1016/j.semnephrol.2012.04.002.CrossRefPubMed

20.

• Moreno-Caceres J, Caja L, Mainez J, Mayoral R, Martin-Sanz P, Moreno-Vicente R, et al. Caveolin-1 is required for TGF-beta-induced transactivation of the EGF receptor pathway in hepatocytes through the activation of the metalloprotease TACE/ADAM17. Cell Death Dis. 2014;5:e1326. doi:10.1038/cddis.2014.294. Although this study does not use kidney cells, it demonstrates the potential for cav-1 to serve as a common regulator of two major profibrotic signaling initiators (TGFβ and EGFR) in diabetic kidney disease.CrossRefPubMedPubMedCentral

21.

Perlman A, Lawsin LM, Kolachana P, Saji M, Moore Jr J, Ringel MD. Angiotensin II regulation of TGF-beta in murine mesangial cells involves both PI3 kinase and MAP kinase. Ann Clin Lab Sci. 2004;34(3):277–86.PubMed

22.

Anguiano L, Riera M, Pascual J, Soler MJ. Endothelin blockade in diabetic kidney disease. J Clin Med. 2015;4(6):1171–92. doi:10.3390/jcm4061171.CrossRefPubMedPubMedCentral

23.

Hua H, Munk S, Whiteside CI. Endothelin-1 activates mesangial cell ERK1/2 via EGF-receptor transactivation and caveolin-1 interaction. Am J Physiol Ren Physiol. 2003;284(2):F303–12. doi:10.1152/ajprenal.00127.2002.CrossRef

24.

Li S, Seitz R, Lisanti MP. Phosphorylation of caveolin by src tyrosine kinases. The alpha-isoform of caveolin is selectively phosphorylated by v-Src in vivo. J Biol Chem. 1996;271(7):3863–8.CrossRefPubMed

25.

Lee H, Volonte D, Galbiati F, Iyengar P, Lublin DM, Bregman DB, et al. Constitutive and growth factor-regulated phosphorylation of caveolin-1 occurs at the same site (Tyr-14) in vivo: identification of a c-Src/Cav-1/Grb7 signaling cassette. Mol Endocrinol. 2000;14(11):1750–75. doi:10.1210/mend.14.11.0553.CrossRefPubMed

26.

Lu Y, Tang L, Li Y, He Q. High glucose-induced fibronectin upregulation in cultured mesangial cells involves caveolin-1-dependent RhoA-GTP activation via Src kinase. Mol Med Rep. 2016;14(1):963–8. doi:10.3892/mmr.2016.5312.PubMed

27.

Wu T, Zhang B, Ye F, Xiao Z. A potential role for caveolin-1 in VEGF-induced fibronectin upregulation in mesangial cells: involvement of VEGFR2 and Src. Am J Physiol Renal Physiol. 2013;304(6):F820–30. doi:10.1152/ajprenal.00294.2012.CrossRefPubMed

28.

Forbes JM, Fukami K, Cooper ME. Diabetic nephropathy: where hemodynamics meets metabolism. Exp Clin Endocrinol Diabetes Off J German Soc Endocrino German Diabet Assoc. 2007;115(2):69–84. doi:10.1055/s-2007-949721.CrossRef

29.

Chen J, Chen JK, Harris RC. Angiotensin II induces epithelial-to-mesenchymal transition in renal epithelial cells through reactive oxygen species/Src/caveolin-mediated activation of an epidermal growth factor receptor-extracellular signal-regulated kinase signaling pathway. Mol Cell Biol. 2012;32(5):981–91. doi:10.1128/MCB.06410-11.CrossRefPubMedPubMedCentral

30.

Wyse BD, Prior IA, Qian H, Morrow IC, Nixon S, Muncke C, et al. Caveolin interacts with the angiotensin II type 1 receptor during exocytic transport but not at the plasma membrane. J Biol Chem. 2003;278(26):23738–46. doi:10.1074/jbc.M212892200.CrossRefPubMed

31.

Ren Z, Liang W, Chen C, Yang H, Singhal PC, Ding G. Angiotensin II induces nephrin dephosphorylation and podocyte injury: role of caveolin-1. Cell Signal. 2012;24(2):443–50. doi:10.1016/j.cellsig.2011.09.022.CrossRefPubMed

32.

Denhez B, Lizotte F, Guimond MO, Jones N, Takano T, Geraldes P. Increased SHP-1 protein expression by high glucose levels reduces nephrin phosphorylation in podocytes. J Biol Chem. 2015;290(1):350–8. doi:10.1074/jbc.M114.612721.CrossRefPubMed

33.

New LA, Martin CE, Scott RP, Platt MJ, Keyvani Chahi A, Stringer CD, et al. Nephrin tyrosine phosphorylation is required to stabilize and restore podocyte foot process architecture. J Am Soc Nephrol. 2016;27(8):2422–35. doi:10.1681/ASN.2015091048.CrossRefPubMed

34.

Gorin Y, Block K. Nox as a target for diabetic complications. Clin Sci. 2013;125(8):361–82. doi:10.1042/CS20130065.CrossRefPubMed

35.

Hilenski LL, Clempus RE, Quinn MT, Lambeth JD, Griendling KK. Distinct subcellular localizations of Nox1 and Nox4 in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2004;24(4):677–83. doi:10.1161/01.ATV.0000112024.13727.2c.CrossRefPubMed

36.

Vilhardt F, van Deurs B. The phagocyte NADPH oxidase depends on cholesterol-enriched membrane microdomains for assembly. EMBO J. 2004;23(4):739–48. doi:10.1038/sj.emboj.7600066.CrossRefPubMedPubMedCentral

37.

Zhang AY, Yi F, Zhang G, Gulbins E, Li PL. Lipid raft clustering and redox signaling platform formation in coronary arterial endothelial cells. Hypertension. 2006;47(1):74–80. doi:10.1161/10.1161/01.HYP.0000196727.53300.62.CrossRefPubMed

38.

Zhang Y, Peng F, Gao B, Ingram AJ, Krepinsky JC. Mechanical strain-induced RhoA activation requires NADPH oxidase-mediated ROS generation in caveolae. Antioxid Redox Signal. 2010;13(7):959–73. doi:10.1089/ars.2009.2908.CrossRefPubMed

39.

Meier M, Park JK, Overheu D, Kirsch T, Lindschau C, Gueler F, et al. Deletion of protein kinase C-beta isoform in vivo reduces renal hypertrophy but not albuminuria in the streptozotocin-induced diabetic mouse model. Diabetes. 2007;56(2):346–54. doi:10.2337/db06-0891.CrossRefPubMed

40.

Ohshiro Y, Ma RC, Yasuda Y, Hiraoka-Yamamoto J, Clermont AC, Isshiki K, et al. Reduction of diabetes-induced oxidative stress, fibrotic cytokine expression, and renal dysfunction in protein kinase Cbeta-null mice. Diabetes. 2006;55(11):3112–20. doi:10.2337/db06-0895.CrossRefPubMed

41.

• Sun LN, Liu XC, Chen XJ, Guan GJ, Liu G. Curcumin attenuates high glucose-induced podocyte apoptosis by regulating functional connections between caveolin-1 phosphorylation and ROS. Acta Pharmacol Sin. 2016;37(5):645–55. doi:10.1038/aps.2015.159. This paper demonstrated the importance of cav-1 Y14 phosphorylation to high glucose-induced ROS generation, extending prior findings on the important role of cav-1 in the oxidative stress response to glucose in kidney cells.

42.

• Wu D, Yang X, Zheng T, Xing S, Wang J, Chi J, et al. A novel mechanism of action for salidroside to alleviate diabetic albuminuria: effects on albumin transcytosis across glomerular endothelial cells. Am J Physiol Endocrinol Metab. 2016;310(3):E225–37. doi:10.1152/ajpendo.00391.2015. This is one of two studies evaluating inhibition of caveolae with cyclodextrin in vivo in diabetic kidney disease. Intraperitoneal administration attenuated proteinuria in type 2 diabetic mice in both early and late treatment groups, supporting in vitro studies that showed caveolae regulate albumin traffic across endothelial cells and podocytes.

43.

Heilig CW, Deb DK, Abdul A, Riaz H, James LR, Salameh J, et al. GLUT1 regulation of the pro-sclerotic mediators of diabetic nephropathy. Am J Nephrol. 2013;38(1):39–49. doi:10.1159/000351989.CrossRefPubMed

44.

Tang SC, Lai KN. The pathogenic role of the renal proximal tubular cell in diabetic nephropathy. Nephrol Dial Transplant Off Pub Eur Dial Transplant Assoc Eur Ren Assoc. 2012;27(8):3049–56. doi:10.1093/ndt/gfs260.

45.

Elvira B, Honisch S, Almilaji A, Pakladok T, Liu G, Shumilina E, et al. Up-regulation of Na(+)-coupled glucose transporter SGLT1 by caveolin-1. Biochim Biophys Acta. 2013;1828(11):2394–8. doi:10.1016/j.bbamem.2013.06.007.CrossRefPubMed

46.

• Lee YJ, Kim MO, Ryu JM, Han HJ. Regulation of SGLT expression and localization through Epac/PKA-dependent caveolin-1 and F-actin activation in renal proximal tubule cells. Biochim Biophys Acta. 2012;1823(4):971–82. doi:10.1016/j.bbamcr.2011.12.011. This study is the first to show the importance of cav-1 to the trafficking of sodium/glucose cotransporters SGLT1 and 2 to the plasma membrane to increase cellular glucose uptake in kidney cells, suggesting a role for cav-1 in pathologic glucose uptake in the diabetic kidney.

47.

Rauch MC, Ocampo ME, Bohle J, Amthauer R, Yanez AJ, Rodriguez-Gil JE, et al. Hexose transporters GLUT1 and GLUT3 are colocalized with hexokinase I in caveolae microdomains of rat spermatogenic cells. J Cell Physiol. 2006;207(2):397–406. doi:10.1002/jcp.20582.CrossRefPubMed

48.

Demova H, Komers R. Determination of caveolin-1 in renal caveolar and non-caveolar fractions in experimental type 1 diabetes. Phytother Res / Academia Scientiarum Bohemoslovaca. 2009;58(4):563–8.

49.

• Moriyama T, Takei T, Itabashi M, Uchida K, Tsuchiya K, Nitta K. Caveolae may enable albumin to enter human renal glomerular endothelial cells. J Cell Biochem. 2015;116(6):1060–9. doi:10.1002/jcb.25061. This study suggests that caveolae play a role in the pathogenesis of albuminuria through allowing endothelial cell albumin uptake and thereby transglomerular passage.

50.

Demova H, Cerna M. RhoA distribution in renal caveolar fractions in experimental type 1 diabetes. Folia Biol. 2011;57(4):139–44.

51.

Pascariu M, Bendayan M, Ghitescu L. Correlated endothelial caveolin overexpression and increased transcytosis in experimental diabetes. J Histochem Cytochem Off J Histochemistry Soc. 2004;52(1):65–76.CrossRef

52.

• Dobrinskikh E, Okamura K, Kopp JB, Doctor RB, Blaine J. Human podocytes perform polarized, caveolae-dependent albumin endocytosis. Am J Physiol Renal Physiol. 2014;306(9):F941–51. doi:10.1152/ajprenal.00532.2013. This study increases understanding of physiologic albumin handling by podocytes and its dependence on caveolae, which may be relevant to proteinuria in diabetic kidney disease.

53.

Castrop H, Schiessl IM. Novel routes of albumin passage across the glomerular filtration barrier. Acta Physiol. 2016. doi:10.1111/apha.12760.

54.

•• Wan X, Chen Z, Choi WI, Gee HY, Hildebrandt F, Zhou W. Loss of epithelial membrane protein 2 aggravates podocyte injury via upregulation of caveolin-1. J Am Soc Nephrol. 2016;27(4):1066–75. doi:10.1681/ASN.2014121197. Using a zebrafish model, this study elegantly demonstrates that cav-1 overexpression in podocytes induces mild proteinuria (when proximal tubule protein reabsorption is inhibited), and increases proteinuria after induction of podocyte injury. These data support the notion that increased cav-1 in diabetic kidneys may contribute to proteinuria.

55.••

Merscher-Gomez S, Guzman J, Pedigo CE, Lehto M, Aguillon-Prada R, Mendez A, et al. Cyclodextrin protects podocytes in diabetic kidney disease. Diabetes. 2013;62(11):3817–27. doi:10.2337/db13-0399. This is one of two studies evaluating inhibition of caveolae with cyclodextrin in vivo in diabetic kidney disease. In a type 2 diabetes model, subcutaneous administration decreased albuminuria and glomerular sclerosis and interestingly also improved glucose control. It also demonstrated specific effects of serum from patients with diabetic kidney disease (but not diabetes) on cav-1 phosphorylation and localization (to focal adhesions), and thereby RhoA activation, in podocytes.

56.

Takahashi T, Harris RC. Role of endothelial nitric oxide synthase in diabetic nephropathy: lessons from diabetic eNOS knockout mice. J Ddiabet Res. 2014;2014:590541. doi:10.1155/2014/590541.

57.

Drab M, Verkade P, Elger M, Kasper M, Lohn M, Lauterbach B, et al. Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice. Science. 2001;293(5539):2449–52. doi:10.1126/science.1062688.CrossRefPubMed

58.

Woodman OL, Missen MA, Boujaoude M. Daidzein and 17 beta-estradiol enhance nitric oxide synthase activity associated with an increase in calmodulin and a decrease in caveolin-1. J Cardiovasc Pharmacol. 2004;44(2):155–63.CrossRefPubMed

59.

Arya A, Yadav HN, Sharma PL. Involvement of vascular endothelial nitric oxide synthase in development of experimental diabetic nephropathy in rats. Mol Cell Biochem. 2011;354(1–2):57–66. doi:10.1007/s11010-011-0805-6.CrossRefPubMed

60.

Komers R, Schutzer WE, Reed JF, Lindsley JN, Oyama TT, Buck DC, et al. Altered endothelial nitric oxide synthase targeting and conformation and caveolin-1 expression in the diabetic kidney. Diabetes. 2006;55(6):1651–9. doi:10.2337/db05-1595.CrossRefPubMed

61.

Sun LN, Yang ZY, Lv SS, Liu XC, Guan GJ, Liu G. Curcumin prevents diabetic nephropathy against inflammatory response via reversing caveolin-1 Tyr14 phosphorylation influenced TLR4 activation. Int Immunopharmacol. 2014;23(1):236–46. doi:10.1016/j.intimp.2014.08.023.CrossRefPubMed

62.

Sun LN, Chen ZX, Liu XC, Liu HY, Guan GJ, Liu G. Curcumin ameliorates epithelial-to-mesenchymal transition of podocytes in vivo and in vitro via regulating caveolin-1. Biomed Pharmacother Biomedecine & pharmacotherapie. 2014;68(8):1079–88. doi:10.1016/j.biopha.2014.10.005.CrossRef

63.

Taniguchi K, Xia L, Goldberg HJ, Lee KW, Shah A, Stavar L, et al. Inhibition of Src kinase blocks high glucose-induced EGFR transactivation and collagen synthesis in mesangial cells and prevents diabetic nephropathy in mice. Diabetes. 2013;62(11):3874–86. doi:10.2337/db12-1010.CrossRefPubMedPubMedCentral

64.

Gojo A, Utsunomiya K, Taniguchi K, Yokota T, Ishizawa S, Kanazawa Y, et al. The Rho-kinase inhibitor, fasudil, attenuates diabetic nephropathy in streptozotocin-induced diabetic rats. Eur J Pharmacol. 2007;568(1–3):242–7. doi:10.1016/j.ejphar.2007.04.011.CrossRefPubMed

65.

Kikuchi Y, Yamada M, Imakiire T, Kushiyama T, Higashi K, Hyodo N, et al. A Rho-kinase inhibitor, fasudil, prevents development of diabetes and nephropathy in insulin-resistant diabetic rats. J Endocrinol. 2007;192(3):595–603. doi:10.1677/JOE-06-0045.CrossRefPubMed

66.

Peng F, Wu D, Gao B, Ingram AJ, Zhang B, Chorneyko K, et al. RhoA/Rho-kinase contribute to the pathogenesis of diabetic renal disease. Diabetes. 2008;57(6):1683–92. doi:10.2337/db07-1149.CrossRefPubMed

67.

Jin J, Peng C, Wu SZ, Chen HM, Zhang BF. Blocking VEGF/Caveolin-1 signaling contributes to renal protection of fasudil in streptozotocin-induced diabetic rats. Acta Pharmacol Sin. 2015;36(7):831–40. doi:10.1038/aps.2015.23.CrossRefPubMedPubMedCentral

68.

Komers R. Rho kinase inhibition in diabetic kidney disease. Br J Clin Pharmacol. 2013;76(4):551–9. doi:10.1111/bcp.12196.PubMedPubMedCentral

69.

Anderson S, Rennke HG, Brenner BM. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest. 1986;77(6):1993–2000. doi:10.1172/JCI112528.CrossRefPubMedPubMedCentral

70.

Thyberg J. Caveolae and cholesterol distribution in vascular smooth muscle cells of different phenotypes. J Histochem Cytochem J Hist Soc. 2002;50(2):185–95.CrossRef

71.

Pojoga LH, Romero JR, Yao TM, Loutraris P, Ricchiuti V, Coutinho P, et al. Caveolin-1 ablation reduces the adverse cardiovascular effects of N-omega-nitro-L-arginine methyl ester and angiotensin II. Endocrinology. 2010;151(3):1236–46. doi:10.1210/en.2009-0514.CrossRefPubMedPubMedCentral

72.

•• Guan TH, Chen G, Gao B, Janssen MR, Uttarwar L, Ingram AJ, et al. Caveolin-1 deficiency protects against mesangial matrix expansion in a mouse model of type 1 diabetic nephropathy. Diabetologia. 2013;56(9):2068–77. doi:10.1007/s00125-013-2968-z. Using cav-1 deficient mice, which also lack caveolae, this study definitively showed a role for cav-1/caveolae in the pathogenesis of glomerular sclerosis and albuminuria in diabetes.

73.

Menne J, Park JK, Boehne M, Elger M, Lindschau C, Kirsch T, et al. Diminished loss of proteoglycans and lack of albuminuria in protein kinase C-alpha-deficient diabetic mice. Diabetes. 2004;53(8):2101–9.CrossRefPubMed

74.

Kim MY, Lim JH, Youn HH, Hong YA, Yang KS, Park HS, et al. Resveratrol prevents renal lipotoxicity and inhibits mesangial cell glucotoxicity in a manner dependent on the AMPK-SIRT1-PGC1alpha axis in db/db mice. Diabetologia. 2013;56(1):204–17. doi:10.1007/s00125-012-2747-2.CrossRefPubMed

75.

Gildea JJ, Kemp BA, Howell NL, Van Sciver RE, Carey RM, Felder RA. Inhibition of renal caveolin-1 reduces natriuresis and produces hypertension in sodium-loaded rats. Am J Physiol Renal Physiol. 2011;300(4):F914–20. doi:10.1152/ajprenal.00380.2010.CrossRefPubMedPubMedCentral

76.

Zidovetzki R, Levitan I. Use of cyclodextrins to manipulate plasma membrane cholesterol content: evidence, misconceptions and control strategies. Biochim Biophys Acta. 2007;1768(6):1311–24. doi:10.1016/j.bbamem.2007.03.026.CrossRefPubMedPubMedCentral

77.

Gould S, Scott RC. 2-Hydroxypropyl-beta-cyclodextrin (HP-beta-CD): a toxicology review. Food Chem Toxicol. 2005;43(10):1451–9. doi:10.1016/j.fct.2005.03.007.CrossRefPubMed

78.

Tourkina E, Richard M, Gooz P, Bonner M, Pannu J, Harley R, et al. Antifibrotic properties of caveolin-1 scaffolding domain in vitro and in vivo. Am J Physiol Lung Cell Mol Physiol. 2008;294(5):L843–61. doi:10.1152/ajplung.00295.2007.CrossRefPubMed

79.

Chidlow Jr JH, Greer JJ, Anthoni C, Bernatchez P, Fernandez-Hernando C, Bruce M, et al. Endothelial caveolin-1 regulates pathologic angiogenesis in a mouse model of colitis. Gastroenterology. 2009;136(2):575–84. doi:10.1053/j.gastro.2008.10.085. e2.CrossRefPubMed

80.

Liu Y, Lu S, Zhang Y, Wang X, Kong F, Liu Y, et al. Role of caveolae in high glucose and TGF-beta(1) induced fibronectin production in rat mesangial cells. Int J Clin Exp Pathol. 2014;7(12):8381–90.PubMedPubMedCentral

81.

Bernatchez P, Sharma A, Bauer PM, Marin E, Sessa WC. A noninhibitory mutant of the caveolin-1 scaffolding domain enhances eNOS-derived NO synthesis and vasodilation in mice. J Clin Invest. 2011;121(9):3747–55. doi:10.1172/JCI44778.CrossRefPubMedPubMedCentral

82.

Castello-Cros R, Whitaker-Menezes D, Molchansky A, Purkins G, Soslowsky LJ, Beason DP, et al. Scleroderma-like properties of skin from caveolin-1-deficient mice: implications for new treatment strategies in patients with fibrosis and systemic sclerosis. Cell Cycle. 2011;10(13):2140–50. doi:10.4161/cc.10.13.16227.CrossRefPubMedPubMedCentral

83.

Gvaramia D, Blaauboer ME, Hanemaaijer R, Everts V. Role of caveolin-1 in fibrotic diseases. Matrix Biol J Int Soc Mat Biol. 2013;32(6):307–15. doi:10.1016/j.matbio.2013.03.005.CrossRef

84.

Shivshankar P, Brampton C, Miyasato S, Kasper M, Thannickal VJ, Le Saux CJ. Caveolin-1 deficiency protects from pulmonary fibrosis by modulating epithelial cell senescence in mice. Am J Respir Cell Mol Biol. 2012;47(1):28–36. doi:10.1165/rcmb.2011-0349OC.CrossRefPubMedPubMedCentral

85.

Wang XM, Zhang Y, Kim HP, Zhou Z, Feghali-Bostwick CA, Liu F, et al. Caveolin-1: a critical regulator of lung fibrosis in idiopathic pulmonary fibrosis. J Exp Med. 2006;203(13):2895–906. doi:10.1084/jem.20061536.CrossRefPubMedPubMedCentral

86.

Kim S, Lee Y, Seo JE, Cho KH, Chung JH. Caveolin-1 increases basal and TGF-beta1-induced expression of type I procollagen through PI-3 kinase/Akt/mTOR pathway in human dermal fibroblasts. Cell Signal. 2008;20(7):1313–9. doi:10.1016/j.cellsig.2008.02.020.CrossRefPubMed

87.

Percy C, Waters MJ, Gobe G. Caveolins in the repair phase of acute renal failure after oxidative stress. Nephrology (Carlton). 2004;9(6):374–80. doi:10.1111/j.1440-1797.2004.00356.x.CrossRef

88.

Park HC, Yasuda K, Ratliff B, Stoessel A, Sharkovska Y, Yamamoto I, et al. Postobstructive regeneration of kidney is derailed when surge in renal stem cells during course of unilateral ureteral obstruction is halted. Am J Physiol Ren Physiol. 2010;298(2):F357–64. doi:10.1152/ajprenal.00542.2009.CrossRef

89.

Cohen AW, Razani B, Wang XB, Combs TP, Williams TM, Scherer PE, et al. Caveolin-1-deficient mice show insulin resistance and defective insulin receptor protein expression in adipose tissue. Am J Physiol Cell Physiol. 2003;285(1):C222–35. doi:10.1152/ajpcell.00006.2003.CrossRefPubMed

90.

Gonzalez-Munoz E, Lopez-Iglesias C, Calvo M, Palacin M, Zorzano A, Camps M. Caveolin-1 loss of function accelerates glucose transporter 4 and insulin receptor degradation in 3T3-L1 adipocytes. Endocrinology. 2009;150(8):3493–502. doi:10.1210/en.2008-1520.CrossRefPubMed

91.

Otsu K, Toya Y, Oshikawa J, Kurotani R, Yazawa T, Sato M, et al. Caveolin gene transfer improves glucose metabolism in diabetic mice. Am J Physiol Cell Physiol. 2010;298(3):C450–6. doi:10.1152/ajpcell.00077.2009.CrossRefPubMed

92.

Lee IH, Campbell CR, Song SH, Day ML, Kumar S, Cook DI, et al. The activity of the epithelial sodium channels is regulated by caveolin-1 via a Nedd4-2-dependent mechanism. J Biol Chem. 2009;284(19):12663–9. doi:10.1074/jbc.M809737200.CrossRefPubMedPubMedCentral

93.

Wang L, Zhang C, Su X, Lin DH, Wang W. Caveolin-1 deficiency inhibits the basolateral K⁺ channels in the distal convoluted tubule and impairs renal K⁺ and Mg²⁺ transport. J Am Soc Nephrol. 2015;26(11):2678–90. doi:10.1681/ASN.2014070658.CrossRefPubMedPubMedCentral

94.

Cao G, Yang G, Timme TL, Saika T, Truong LD, Satoh T, et al. Disruption of the caveolin-1 gene impairs renal calcium reabsorption and leads to hypercalciuria and urolithiasis. Am J Pathol. 2003;162(4):1241–8. doi:10.1016/S0002-9440(10)63920-X.CrossRefPubMedPubMedCentral

Titel: Caveolin-1 in the Pathogenesis of Diabetic Nephropathy: Potential Therapeutic Target?
verfasst von: Richard Van Krieken
Joan C. Krepinsky
Publikationsdatum: 01.03.2017
Verlag: Springer US
Erschienen in: Current Diabetes Reports / Ausgabe 3/2017
Print ISSN: 1534-4827
Elektronische ISSN: 1539-0829
DOI: https://doi.org/10.1007/s11892-017-0844-9

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Caveolin-1 in the Pathogenesis of Diabetic Nephropathy: Potential Therapeutic Target?

Abstract

Purpose of review

Recent findings

Summary

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

CAR-M-Zellen: Warten auf das große Fressen

Chronische Verstopfung: „Versuchen Sie es mit grünen Kiwis!“

So häufig greift rheumatoide Arthritis auf Organe über

Blutdrucksenkung könnte Uterusmyome verhindern

Update Innere Medizin

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Purpose of review

Recent findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2017

Intestinal Microbiota in Type 2 Diabetes and Chronic Kidney Disease

The Role of Endoplasmic Reticulum Stress in Diabetic Nephropathy

Arsenic Exposure and Type 2 Diabetes: MicroRNAs as Mechanistic Links?

Diet and Diabetic Kidney Disease: Plant Versus Animal Protein

Porcine Islet Xenografts: a Clinical Source of ß-Cell Grafts

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

CAR-M-Zellen: Warten auf das große Fressen

Chronische Verstopfung: „Versuchen Sie es mit grünen Kiwis!“

So häufig greift rheumatoide Arthritis auf Organe über

Blutdrucksenkung könnte Uterusmyome verhindern

Update Innere Medizin